RoACTEMRA.com

EULAR 2011: Key ACTEMRA/RoACTEMRA abstracts

The European League Against Rheumatism (EULAR) has held an annual congress since 2000. The 12th EULAR Annual European Congress of Rheumatology was held on 25–28 May 2011 in London, United Kingdom, and attracted over 16,000 delegates from around the globe. Please click on abstract numbers or titles in the table below to view key ACTEMRA/RoACTEMRA abstracts presented at the congress.

The next EULAR congress will take place on 6–9 June 2012 in Berlin, Germany. Please click here to go to the EULAR annual meeting home page.

EULAR 2011: Key ACTEMRA/RoACTEMRA abstracts

Abstract #	Title	First author
ACTEMRA/RoACTEMRA (tocilizumab) oral presentations
OP0006	Efficacy and safety of tocilizumab in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data	F. De Benedetti
OP0020	Tocilizumab (TCZ) plus methotrexate (MTX) does not have superior clinical efficacy to TCZ alone in RA patients with inadequate response to MTX: 24-week results of the ACT-RAY study	M. Dougados
OP0021	MEASURE: A translational, randomized, placebo (PBO)-controlled study to evaluate the effects of tocilizumab (TCZ) on parameters of lipids and inflammation	I. McInnes
ACTEMRA/RoACTEMRA (tocilizumab) poster presentations
FRI0365	Comparison of tocilizumab as monotherapy or with add-on DMARDS in patients with rheumatoid arthritis and an inadequate response to previous treatments: ACT-SURE results	J. Sibilia
SAT0270	Long-term safety of tocilizumab in rheumatoid arthritis clinical trials	M. Genovese
SAT0282	Early reductions in synovitis and osteitis with tocilizumab therapy are maintained through Week 52: Results from the ACT-RAY MRI substudy	O. Troum